Rebecsinib
Rebecsinib[edit | edit source]
Rebecsinib is a pharmaceutical drug that has been developed as a tyrosine kinase inhibitor (TKI) for the treatment of certain types of cancer. It is specifically designed to target and inhibit the activity of specific tyrosine kinases, which are enzymes involved in the signaling pathways that regulate cell division and survival. By inhibiting these enzymes, rebecsinib aims to slow down or stop the growth of cancer cells.
Mechanism of Action[edit | edit source]
Rebecsinib functions by selectively binding to the ATP-binding site of specific tyrosine kinases. This binding prevents the phosphorylation of tyrosine residues on target proteins, which is a critical step in the activation of signaling pathways that promote cell proliferation and angiogenesis. By blocking these pathways, rebecsinib can effectively reduce tumor growth and metastasis.
Clinical Applications[edit | edit source]
Rebecsinib is primarily used in the treatment of non-small cell lung cancer (NSCLC) and certain types of breast cancer. It has shown efficacy in patients with tumors that express specific genetic mutations, such as those in the EGFR or ALK genes. These mutations often lead to the overactivation of tyrosine kinase pathways, making them suitable targets for rebecsinib therapy.
Side Effects[edit | edit source]
As with many targeted cancer therapies, rebecsinib can cause a range of side effects. Common side effects include:
More serious side effects may include interstitial lung disease, hepatotoxicity, and cardiotoxicity. Patients receiving rebecsinib are closely monitored for these adverse effects.
Development and Approval[edit | edit source]
Rebecsinib was developed by a collaboration between several pharmaceutical companies and research institutions. It underwent extensive clinical trials to evaluate its safety and efficacy. The drug received approval from regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific indications based on the results of these trials.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
